image
Bellerophon Therapeutics, Inc. BLPH
Healthcare - Biotechnology - NASDAQ - US
Watchlist
$ 0.037
0 %
$ 453 K
Market Cap
-0.04
P/E
1. INTRINSIC VALUE

Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness.[ Read More ]

The intrinsic value of one BLPH stock under the base case scenario is HIDDEN Compared to the current market price of 0.037 USD, Bellerophon Therapeutics, Inc. is HIDDEN

BLPH Intrinsic Value
HIDDEN
SHOW
2. FUNDAMENTAL ANALYSIS

Price Chart BLPH

image
FINANCIALS
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-22.4 M OPERATING INCOME
-11.03%
Growth Rates
1Year -11.03%
3Years -8.61%
5Years 1.87%
7Years 9.94%
10Years 7.00%
-19.8 M NET INCOME
-11.69%
Growth Rates
1Year -11.69%
3Years -14.34%
5Years 18.40%
7Years 11.45%
10Years 8.11%
-17.8 M OPERATING CASH FLOW
22.13%
Growth Rates
1Year 22.13%
3Years -11.16%
5Years -2.46%
7Years 12.78%
10Years 6.87%
0 INVESTING CASH FLOW
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 10.41%
10Years 7.18%
-40 K FINANCING CASH FLOW
0.00%
Growth Rates
1Year 0.00%
3Years -0.22%
5Years -0.03%
7Years -0.01%
10Years -0.01%
0 REVENUE
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-2.17 M OPERATING INCOME
58.74%
Growth Rates
1Year -11.03%
3Years -8.61%
5Years 1.87%
7Years 9.94%
10Years 7.00%
-1.92 M NET INCOME
62.61%
Growth Rates
1Year -11.69%
3Years -14.34%
5Years 18.40%
7Years 11.45%
10Years 8.11%
-6.33 M OPERATING CASH FLOW
-28.67%
Growth Rates
1Year 22.13%
3Years -11.16%
5Years -2.46%
7Years 12.78%
10Years 6.87%
140 K INVESTING CASH FLOW
0.00%
Growth Rates
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 10.41%
10Years 7.18%
0 FINANCING CASH FLOW
0.00%
Growth Rates
1Year 0.00%
3Years -0.22%
5Years -0.03%
7Years -0.01%
10Years -0.01%
Balance Sheet Decomposition Bellerophon Therapeutics, Inc.
image
Current Assets 7.56 M
Cash & Short-Term Investments 7.33 M
Receivables 0
Other Current Assets 234 K
Non-Current Assets 372 K
Long-Term Investments 0
PP&E 186 K
Other Non-Current Assets 186 K
Current Liabilities 5.4 M
Accounts Payable 1.23 M
Short-Term Debt 203 K
Other Current Liabilities 3.97 M
Non-Current Liabilities 0
Long-Term Debt 0
Other Non-Current Liabilities 0
EFFICIENCY
Earnings Waterfall Bellerophon Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 65 K
Gross Profit -65 K
Operating Expenses 22.4 M
Operating Income -22.4 M
Other Expenses -2.55 M
Net Income -19.8 M
RATIOS
0.00% GROSS MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0.00% OPERATING MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
0.00% NET MARGIN
0.00%
Averages
1Year 0.00%
3Years 0.00%
5Years 0.00%
7Years 0.00%
10Years 0.00%
-782.60% ROE
-782.60%
Averages
1Year -782.60%
3Years -309.79%
5Years -245.17%
7Years 107.86%
10Years 73.57%
-249.92% ROA
-249.92%
Averages
1Year -249.92%
3Years -121.74%
5Years -90.22%
7Years -97.17%
10Years -268.50%
-787.38% ROIC
-787.38%
Averages
1Year -787.38%
3Years -310.44%
5Years -103.66%
7Years 116.66%
10Years 79.27%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Bellerophon Therapeutics, Inc.
image
Net Income -19.8 M
Depreciation & Amortization 65 K
Capital Expenditures 0
Stock-Based Compensation 786 K
Change in Working Capital 1.21 M
Others 385 K
Free Cash Flow -17.8 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Bellerophon Therapeutics, Inc.
image
BLPH has no price targets from Wall Street.
4. DIVIDEND ANALYSIS
0.00% DIVIDEND YIELD
0 USD DIVIDEND PER SHARE
5. COMPETITION

Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States.

image
1.96 USD
BPTH
Undervalued 141.78%

Capricor Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the development of transformative cell and exosome-based therapeutics for the treatment and prevention of spectrum of diseases and disorders.

image
-12.4 USD
CAPR
Overvalued 166.70%

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

image
0.233 USD
NXTC
Overvalued 82.24%

Zura Bio Limited, a clinical-stage biotechnology company, focuses on developing novel medicines for immune and inflammatory disorders. It develops ZB-168, an anti IL7R a inhibitor that impact on diseases driven by IL7 and TSLP biological pathways; and Torudokimab, a monoclonal antibody that neutralizes IL33, which is in Phase 2 clinical trial development.

image
3.02 USD
ZURA
Overvalued 4.48%

Altamira Therapeutics Ltd. engages in developing therapeutics that address various unmet medical needs. Its commercial products include Bentrio, a drug-free nasal spray for personal protection against airborne viruses and allergens.

image
1.19 USD
CYTO
Undervalued 160.42%

Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia.

image
1.01 USD
IMMX
Overvalued 36.50%

Enveric Biosciences, Inc., a pharmaceutical company, engages in developing various cannabinoid medicines for cancer care. Its products pipeline includes EV104 for the treatment of osteoarthritis; EVM-101 and EVM-201 for the treatment of cancer related distress; EVM-301 for the treatment of mental health indication; EV102, a cannabinoid cream for topical skin application; and EV101, a cannabinoid and chemotherapy combination therapy.

image
1.06 USD
ENVB
Undervalued 190.33%

Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing oral therapies that target serious diseases associated with the breakdown of the mucosal barrier protecting the gastrointestinal tract.

image
13.6 USD
PALI
Undervalued 439.99%
6. Ownership
Insider Ownership Bellerophon Therapeutics, Inc.
image
Sold
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
0 USD 0
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
Date Value Insider Amount Avg Price
1 year ago
Oct 13, 2023
Sell 112 K USD
Puissance Capital Management LP
10 percent owner
- 1076841
 0.1038 USD
1 year ago
Jun 07, 2023
Sell 112 K USD
Puissance Life Science Opportunities Fund VI
10 percent owner
- 134421
 0.83 USD
1 year ago
May 18, 2023
Sell 94.6 K USD
Kim Bobae
VP Reg. Affairs & Quality
- 9455
 10 USD
1 year ago
May 18, 2023
Sell 5.3 M USD
Puissance Life Science Opportunities Fund VI
10 percent owner
- 560000
 9.46 USD
3 years ago
Mar 18, 2021
Sell 2.19 M USD
New Mountain Investments II, LLC
10 percent owner
- 400000
 5.48 USD
4 years ago
Sep 10, 2020
Bought 40.7 K USD
FARES Wassim
Chief Medical Officer
+ 4000
 10.177 USD
4 years ago
Jun 08, 2020
Bought 33.5 K USD
Wang Theodore T
director, 10 percent owner:
+ 2600
 12.867 USD
4 years ago
Jun 05, 2020
Bought 63.4 K USD
Wang Theodore T
director, 10 percent owner:
+ 4986
 12.724 USD
4 years ago
Nov 25, 2019
Bought 2.77 K USD
Wang Theodore T
director, 10 percent owner:
+ 7193
 0.3856 USD
4 years ago
Nov 22, 2019
Bought 394 USD
Wang Theodore T
director, 10 percent owner:
+ 1050
 0.3748 USD
4 years ago
Nov 21, 2019
Bought 74 USD
Wang Theodore T
director, 10 percent owner:
+ 200
 0.37 USD
5 years ago
Oct 24, 2019
Sell 353 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
- 704595
 0.5015 USD
5 years ago
Oct 25, 2019
Sell 25.5 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
- 56242
 0.4536 USD
5 years ago
Oct 28, 2019
Sell 146 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
- 333010
 0.4387 USD
5 years ago
Oct 24, 2019
Sell 353 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
- 704595
 0.5015 USD
5 years ago
Oct 25, 2019
Sell 25.5 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
- 56242
 0.4536 USD
5 years ago
Oct 28, 2019
Sell 146 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
- 333010
 0.4387 USD
5 years ago
Jun 12, 2019
Bought 31.9 K USD
Wang Theodore T
director, 10 percent owner:
+ 50000
 0.6381 USD
5 years ago
May 22, 2019
Bought 16.5 K USD
Wang Theodore T
director, 10 percent owner:
+ 27500
 0.6012 USD
5 years ago
May 21, 2019
Bought 26.4 K USD
Wang Theodore T
director, 10 percent owner:
+ 43280
 0.6093 USD
5 years ago
May 21, 2019
Bought 12.2 K USD
Peacock Jonathan M
Director
+ 20000
 0.6099 USD
5 years ago
May 21, 2019
Bought 2.98 K USD
Tenenbaum Fabian
Chief Executive Officer
+ 5000
 0.595 USD
5 years ago
Jan 23, 2019
Bought 100 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 142857
 0.7 USD
5 years ago
Jan 23, 2019
Bought 100 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 142857
 0.7 USD
5 years ago
Jan 25, 2019
Bought 315 K USD
Wang Theodore T
director, 10 percent owner:
+ 450000
 0.7 USD
5 years ago
Jan 25, 2019
Bought 500 K USD
Peacock Jonathan M
Director
+ 714286
 0.7 USD
5 years ago
Jan 25, 2019
Bought 400 K USD
Amin Naseem
Director
+ 571429
 0.7 USD
6 years ago
Sep 17, 2018
Bought 70.9 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 60000
 1.1824 USD
6 years ago
Sep 14, 2018
Bought 92.2 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 75000
 1.23 USD
6 years ago
Sep 13, 2018
Bought 89.2 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 75000
 1.1888 USD
6 years ago
Sep 17, 2018
Bought 70.9 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 60000
 1.1824 USD
6 years ago
Sep 14, 2018
Bought 92.2 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 75000
 1.23 USD
6 years ago
Sep 13, 2018
Bought 89.2 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 75000
 1.1888 USD
6 years ago
Sep 12, 2018
Bought 85.9 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 75000
 1.1455 USD
6 years ago
Sep 11, 2018
Bought 229 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 200000
 1.1442 USD
6 years ago
Sep 10, 2018
Bought 244 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 200000
 1.2182 USD
6 years ago
Sep 12, 2018
Bought 85.9 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 75000
 1.1455 USD
6 years ago
Sep 11, 2018
Bought 229 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 200000
 1.1442 USD
6 years ago
Sep 10, 2018
Bought 244 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 200000
 1.2182 USD
6 years ago
Sep 07, 2018
Bought 53.7 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 60000
 0.8957 USD
6 years ago
Sep 06, 2018
Bought 42.1 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 50000
 0.8419 USD
6 years ago
Sep 05, 2018
Bought 42.3 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 50000
 0.8465 USD
6 years ago
Sep 07, 2018
Bought 53.7 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 60000
 0.8957 USD
6 years ago
Sep 06, 2018
Bought 42.1 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 50000
 0.8419 USD
6 years ago
Sep 05, 2018
Bought 42.3 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 50000
 0.8465 USD
6 years ago
Aug 16, 2018
Bought 43.1 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 66393
 0.6493 USD
6 years ago
Aug 15, 2018
Bought 176 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 272000
 0.6467 USD
6 years ago
Aug 14, 2018
Bought 124 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 190977
 0.6486 USD
6 years ago
Aug 16, 2018
Bought 43.1 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 66393
 0.6493 USD
6 years ago
Aug 15, 2018
Bought 176 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 272000
 0.6467 USD
6 years ago
Aug 14, 2018
Bought 124 K USD
VENROCK ASSOCIATES IV L P
10 percent owner
+ 190977
 0.6486 USD
7 years ago
Nov 29, 2016
Bought 1.54 M USD
Linde North America, Inc.
10 percent owner
+ 1920000
 0.8 USD
7 years ago
Sep 29, 2017
Bought 2.14 M USD
Linde North America, Inc.
10 percent owner
+ 1721992
 1.242 USD
7 years ago
Sep 29, 2017
Bought 550 K USD
Amin Naseem
Director
+ 456432
 1.205 USD
7 years ago
Sep 29, 2017
Bought 567 K USD
Amin Naseem
Director
+ 456432
 1.242 USD
7 years ago
Sep 29, 2017
Bought 12 K USD
Luehring Jens
director, 10 percent owner:
+ 10000
 1.205 USD
7 years ago
Sep 29, 2017
Bought 12.4 K USD
Luehring Jens
director, 10 percent owner:
+ 10000
 1.242 USD
7 years ago
Sep 29, 2017
Bought 300 K USD
Peacock Jonathan M
Director
+ 248962
 1.205 USD
7 years ago
Sep 29, 2017
Bought 309 K USD
Peacock Jonathan M
Director
+ 248962
 1.242 USD
7 years ago
Dec 09, 2016
Bought 11.2 K USD
Luehring Jens
director, 10 percent owner:
+ 20000
 0.56 USD
7 years ago
Nov 29, 2016
Bought 500 K USD
Amin Naseem
Director
+ 714285
 0.7 USD
7 years ago
Nov 29, 2016
Bought 571 K USD
Amin Naseem
Director
+ 714285
 0.8 USD
7 years ago
Nov 29, 2016
Bought 100 K USD
Tenenbaum Fabian
Chief Executive Officer
+ 142857
 0.7 USD
7 years ago
Nov 29, 2016
Bought 114 K USD
Tenenbaum Fabian
Chief Executive Officer
+ 142857
 0.8 USD
7 years ago
Nov 29, 2016
Bought 200 K USD
Peacock Jonathan M
Director
+ 285715
 0.7 USD
7 years ago
Nov 29, 2016
Bought 229 K USD
Peacock Jonathan M
Director
+ 285715
 0.8 USD
8 years ago
May 17, 2016
Bought 6.84 K USD
Peacock Jonathan M
President and CEO
+ 5000
 1.3683 USD
8 years ago
Dec 16, 2015
Bought 35.3 K USD
Peacock Jonathan M
President and CEO
+ 12800
 2.7606 USD
8 years ago
Dec 15, 2015
Bought 20.4 K USD
Peacock Jonathan M
President and CEO
+ 7500
 2.72 USD
9 years ago
Aug 19, 2015
Bought 27.4 K USD
Peacock Jonathan M
President and CEO
+ 5000
 5.4754 USD
9 years ago
May 20, 2015
Bought 5.98 K USD
MEGLASSON MARTIN
Chief Scientific Officer
+ 712
 8.4 USD
9 years ago
May 20, 2015
Bought 48.3 K USD
Peacock Jonathan M
President and CEO
+ 5560
 8.6912 USD
9 years ago
Feb 19, 2015
Bought 2.55 M USD
ARCH VENTURE FUND VI LP
10 percent owner
+ 212666
 12 USD
9 years ago
Feb 19, 2015
Bought 2.55 M USD
NELSEN ROBERT
director, 10 percent owner:
+ 212666
 12 USD
9 years ago
Feb 19, 2015
Bought 12.8 M USD
New Mountain Investments II, LLC
10 percent owner
+ 1070166
 12 USD
9 years ago
Feb 19, 2015
Bought 12.8 M USD
Weinstein Adam
director, 10 percent owner:
+ 1070166
 12 USD
9 years ago
Feb 19, 2015
Bought 12.8 M USD
Holt Matthew S.
director, 10 percent owner:
+ 1070166
 12 USD
9 years ago
Feb 19, 2015
Bought 4.31 M USD
Linde North America, Inc.
10 percent owner
+ 358916
 12 USD
9 years ago
Feb 19, 2015
Bought 4.31 M USD
Luehring Jens
director, 10 percent owner:
+ 358916
 12 USD
9 years ago
Feb 19, 2015
Bought 300 K USD
Tasse Daniel
Director
+ 25000
 12 USD
9 years ago
Feb 19, 2015
Bought 18 K USD
Heyrman Reinilde
Chief Clinical Dev. Officer
+ 1500
 12 USD
9 years ago
Feb 19, 2015
Bought 144 K USD
MEGLASSON MARTIN
Chief Scientific Officer
+ 12000
 12 USD
9 years ago
Feb 19, 2015
Bought 18 K USD
Naidu Manesh
Chief Business Officer
+ 1500
 12 USD
9 years ago
Feb 19, 2015
Bought 250 K USD
Peacock Jonathan M
President and CEO
+ 20800
 12 USD
7. News
Why Is Bellerophon Therapeutics (BLPH) Stock Down 34% Today? Bellerophon Therapeutics (NASDAQ: BLPH ) stock is losing value on Tuesday after the clinical-stage therapeutics company was sent a delisting notice. The Listing Qualifications Department for the Nasdaq Exchange has decided to delist shares of BLPH stock come Friday unless it requests a meeting with the Nasdaq Hearings Panel. investorplace.com - 1 year ago
Top 5 Health Care Stocks That Could Lead To Your Biggest Gains In July - Cibus (NASDAQ:CBUS), Bellerophon Therapeutics (NASDAQ:BLPH) The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies. benzinga.com - 1 year ago
Bellerophon (BLPH) Down 87% as Lung Disease Candidate Fails Bellerophon's (BLPH) shares fall as a late-stage study of INOpulse to treat fibrotic interstitial lung disease fails to meet its primary endpoint. zacks.com - 1 year ago
Is Bellerophon Therapeutics (BLPH) Outperforming Other Medical Stocks This Year? Here is how Bellerophon Therapeutics (BLPH) and ANI Pharmaceuticals (ANIP) have performed compared to their sector so far this year. zacks.com - 1 year ago
Bellerphon Therapeutics stock plunges toward record selloff after lung disease treatment performs worse than placebo in late-stage trial Shares of Bellerophon Therapeutics Inc. BLPH, -83.00% plummeted 83% toward a record one-day decline, after the biotherapeutics company said its lung-disease treatment failed to meet its primary endpoint in a Phase 3 “Rebuild” study. The company said its INOpulse for the treatment of fibrotic Interstitial Lung Disease (fILD) performed worse than placebo, while the secondary endpoints demonstrated “minimal difference” between studied groups, with none approaching statistical significance. marketwatch.com - 1 year ago
Why Is Bellerophon Therapeutics (BLPH) Stock Down 79% Today? Bellerophon Therapeutics (NASDAQ: BLPH ) stock is taking a massive beating on Monday after the pharmaceutical company posted poor clinical trial results. The bad news for BLPH stock comes from its Phase 3 clinical trial of INOpulse as a treatment for fibrotic Interstitial Lung Disease (fILD). investorplace.com - 1 year ago
5 Stocks With Recent Price Strength Amid March Rally Investors target stocks that are witnessing a bullish run. Some of the stocks seeing price strength are BLPH, CRD.B, REPX, HROW and LNTH. zacks.com - 1 year ago
Bellerophon Therapeutics (BLPH) Is a Great Choice for 'Trend' Investors, Here's Why Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. zacks.com - 1 year ago
Here's Why Momentum in Bellerophon Therapeutics (BLPH) Should Keep going Bellerophon Therapeutics (BLPH) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen. zacks.com - 1 year ago
How to Find Cheap Penny Stocks to Make Money Trading Use these tips for finding cheap penny stocks to buy The post How to Find Cheap Penny Stocks to Make Money Trading  appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. pennystocks.com - 1 year ago
5 Hot Penny Stocks Exploding After News This Week Hot penny stocks with news to watch this week. The post 5 Hot Penny Stocks Exploding After News This Week appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com. pennystocks.com - 1 year ago
Bellerophon (BLPH) Receives FDA Acceptance to Reduce Study Size Bellerophon's (BLPH) proposal to reduce the size of its ongoing phase III REBUILD study of INOpulse in fibrotic Interstitial Lung Disease gets accepted by the FDA. Stock up. zacks.com - 2 years ago
8. Profile Summary

Bellerophon Therapeutics, Inc. BLPH

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 453 K
Dividend Yield 0.00%
Description Bellerophon Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its product includes INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension. The company engages in the development of INOpulse that is in Phase 3 clinical trial for the treatment of pulmonary hypertension associated with fibrotic interstitial lung disease; which has completed Phase 2a clinical trial for pulmonary hypertension associated with chronic obstructive pulmonary disease; and that has completed Phase 2 dose escalation stage for pulmonary hypertension associated with sarcoidosis, as well as for chronic thromboembolic pulmonary hypertension and pulmonary hypertension associated with pulmonary edema from high altitude sickness. The company was formerly known as Ikaria Development LLC and changed its name to Bellerophon Therapeutics, Inc. in January 2014. Bellerophon Therapeutics, Inc. was founded in 2009 and is headquartered in Warren, New Jersey.
Contact 184 Liberty Corner Road, Warren, NJ, 07059 https://bellerophon.com
IPO Date Feb. 13, 2015
Employees 18
Officers Mr. Craig R. Jalbert CIRA President, Treasurer, Secretary, Principal Executive, Financial & Accounting Officer and Director